The study of the effect of comorbidities on pharmacotherapy of patients with liver cirrhosis


  • I. O. Fedyak SHHE «Ivano-Frankivsk National Medical University», Ukraine
  • O. V. Maksymenko SHHE «Ivano-Frankivsk National Medical University», Ukraine



cirrhosis, comorbidity, frequency analysis, VEN analysis, drugs used to treat liver diseases


Recently, the incidence of liver cirrhosis has been increasing and the mortality is still high. The death rate from liver cirrhosis is 2% of all deaths of the world’s population, and mortality is on the 5th place. The subject of the study was 190 medical records of patients diagnosed with liver cirrhosis in the Department of Gastroenterology of Ivano-Frankivsk Regional Clinical Hospital for 2012-2013. According to the analysis of gender, age, social characteristics, the area of residence and comorbidities in 190 patients with LC their generalized portrait has been represented. This is a man aged 51-60, who mostly comes from rural areas (57.4%), does not work in 66% of cases and has such comorbidities as chronic pancreatitis (66.3%), chronic gastroduodenitis (54.2%), chronic cholecystitis (48.9%). The results of frequency and formal VEN analyses of medication administration records of the patients indicate that they received substantial treatment of comorbidities (55% of the drugs prescribed). To optimize the treatment of patients with LC it is necessary, first of all, to develop a new protocol of medical care to patients with LC taking into account the data of evidence-based medicine, pharmacoeconomics and coordination with regulatory lists of drugs. It has been shown that the simultaneous treatment of LC and comorbidities leads to polypharmacy.


Abragamovych M.O., Farmaga M.L. // Lviv Clinical Herald. – 2013. – №2. – P. 37-45.

Babak O.Ya., Harchenko N.V. Rational diagnostics and pharmacotherapy of the digestive system diseases: Doctor’s reference Gastroenterologist. – Kiev: “Doctor-Media”, 2007. − 308 p.

Bruce A. Runyon // Hepatol. – 2013. – Vol. 57. – Р. 1651-1653.

Cirrhosis [Electronic resource] / Verneda Lights, Jennifer Nelson // Medically Reviewed Publishedon. – 2012. – Access mode :

Detlef Schuppan, Nezam H. Afdhal // Lancet. – 2008. – Vol. 371. – P. 838-851.

Eric Gershwin M., Selmi C., Worman H.J. et al. // Hepatol. – 2005. – Vol. 42. – Р. 1194-1202.

Fedyak I.O., Maksymenko O.V. Urgency use pharmacoeconomic approach to optimize the treatment of patients with cirrhosis [Text] // Pharmacoeconomics in Ukraine: state and prospects of development of materials science and practical VI. Conf. – Kh., 2013. – P. 246-247.

Jepsen P. // World J. Gastroenterol. – 2014. – Vol. 20 (23). – Р. 7223-7230. [Electronic resource] – Access mode:

Jepsen P., Vilstrup H., P. Kragh Andersen et al. // Hepatol. – 2008. – Vol. 48. – P. 214-220.

Mokdad Al., Lopez Al.D., Shahraz S. et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis // BMC Medicine. – 2014. [Electronic resource] – Access mode : http://www.

Samogalska O.Ye., Karpenko N.V. // Herald of Sci. Res. – 2008. – №2. – P. 19-21.

Tkacheva O.V., Minova K.O. Frequency analysis of drugs for the treatment of liver cirrhosis in hospital in Kharkiv [Text] // Pharmacoeconomics in Ukraine: state and prospects of development of materials science VI -pract. conf. – Kh., 2014. – P. 55-56.

Williams R., Aspinall R., Bellis M. et al. // The Lancet. – 2014. – Vol. 384, №9958. – Р. 1953-1997. [Electronic resource] – Access mode: pdfs/journals/lancet/PIIS0140-6736(14)61838-9.pdf.